[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. McDougal A, Sethi Gupta M, Ramamoorthy K, Sun G, Safe SH: Inhibition of carcinogen-induced rat mammary tumor growth and other estrogen-dependent responses by symmetrical dihalo-substituted analogs of diindolylmethane. Cancer Lett; 2000 Apr 14;151(2):169-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DihaloDIMs (100 mg/kg/dayx3) were not estrogenic in the immature female B6C3F1 mouse uterus; however, in animals co-treated with E2 (0.02 microg/mouse), 5,5'-dichloro- and 6,6'-dichloroDIM inhibited uterine progesterone receptor (PR) binding and uterine peroxidase activity, whereas 5,5'-dichloro- and 5,5'-dichloro-2,2'-dimethylDIM inhibited only the latter response.
  • 4,4'-Dichloro-, 5,5'-dibromo- and 6,6'-dichloroDIM, significantly inhibited mammary tumor growth at doses of 1 mg/kg every second day, and no significant changes in organ weights or liver and kidney histopathology were observed.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Carcinogens / toxicity. Estradiol / pharmacology. Indoles / pharmacology. Mammary Neoplasms, Animal / chemically induced. Mammary Neoplasms, Animal / pathology
  • [MeSH-minor] Animals. Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Cell Division / drug effects. Dose-Response Relationship, Drug. Estrogen Antagonists / chemistry. Estrogen Antagonists / pharmacology. Estrogen Antagonists / therapeutic use. Female. Halogens / metabolism. Humans. Mice. Organ Size / drug effects. Peroxidase / metabolism. Rats. Rats, Sprague-Dawley. Receptors, Progesterone / metabolism. Tumor Cells, Cultured. Uterus / drug effects. Uterus / enzymology. Uterus / growth & development. Uterus / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10738111.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / ES09106
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] IRELAND
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents; 0 / Carcinogens; 0 / Estrogen Antagonists; 0 / Halogens; 0 / Indoles; 0 / Receptors, Progesterone; 4TI98Z838E / Estradiol; EC 1.11.1.7 / Peroxidase; SSZ9HQT61Z / 3,3'-diindolylmethane
  •  go-up   go-down


2. Jie JZ, Wang JW, Qu JG, Hung T: Suppression of human colon tumor growth by adenoviral vector-mediated NK4 expression in an athymic mouse model. World J Gastroenterol; 2007 Apr 7;13(13):1938-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of human colon tumor growth by adenoviral vector-mediated NK4 expression in an athymic mouse model.
  • AIM: To investigate the suppressive effects of adenoviral vector-mediated expression of NK4, an antagonist of hepatocyte growth factor (HGF), on human colon cancer in an athymic mouse model to explore the possibility of applying NK4 to cancer gene therapy.
  • METHODS: A human colon tumor model was developed by subcutaneous implantation of tumor tissue formed by LS174T cells grown in athymic mice.
  • Fifteen tumor-bearing mice were randomized into three groups (n = 5 in each group) at d 3 after tumor implantation and mice were injected intratumorally with phosphate-buffered saline (PBS) or with recombinant adenovirus expressing beta-galactosidase (Ad-LacZ) or NK4 (rvAdCMV/NK4) at a 6-d interval for total 5 injections in each mouse.
  • Tumor sizes were measured during treatment to draw a tumor growth curve.
  • At d 26 after the first treatment, all animals were sacrificed and the tumors were removed to immunohistochemically examine proliferating cell nuclear antigen (PCNA), microvessel density (represented by CD31), and apoptotic cells.
  • These mice were randomized into 3 groups (n = 5 in each group) at d 1 after injection and were treated by ip injection of PBS, or Ad-LacZ, or rvAdCMV/NK4 at a 6-d interval for total two injections in each mouse.
  • These findings indicate that NK4 gene transfer may be an effective tool for the treatment of colon cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Colonic Neoplasms / therapy. Genetic Therapy. Hepatocyte Growth Factor / genetics. Hepatocyte Growth Factor / metabolism. Xenograft Model Antitumor Assays / methods

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 1997 Dec 22;420(1):1-6 [9450538.001]
  • [Cites] Cancer Invest. 1997;15(6):513-21 [9412656.001]
  • [Cites] Int J Cancer. 1998 Mar 30;76(1):105-14 [9533769.001]
  • [Cites] Clin Cancer Res. 1995 Feb;1(2):147-54 [9815967.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14417-22 [9826715.001]
  • [Cites] Oncogene. 1998 Nov 26;17(21):2691-700 [9840933.001]
  • [Cites] Crit Rev Oncol Hematol. 1999 Feb;29(3):209-48 [10226727.001]
  • [Cites] Cancer Gene Ther. 2005 Feb;12(2):206-16 [15486556.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 29;333(2):316-27 [15950947.001]
  • [Cites] Cancer Gene Ther. 2006 May;13(5):520-9 [16341142.001]
  • [Cites] World J Gastroenterol. 2006 Jul 7;12(25):3983-8 [16810744.001]
  • [Cites] J Hepatol. 2006 Nov;45(5):688-95 [16839638.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3695-703 [10589789.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1442-8 [10728711.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1761-5 [10749151.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6737-43 [11118060.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):864-73 [11259105.001]
  • [Cites] Curr Drug Targets. 2001 Mar;2(1):41-55 [11465538.001]
  • [Cites] Cancer Gene Ther. 2002 Oct;9(10):799-806 [12224019.001]
  • [Cites] Cancer Sci. 2003 Apr;94(4):321-7 [12824898.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4578-85 [14555533.001]
  • [Cites] Cancer Sci. 2004 Apr;95(4):321-7 [15072590.001]
  • [Cites] Cancer Gene Ther. 2004 Jun;11(6):431-40 [15118756.001]
  • [Cites] Eur J Cancer. 2004 Sep;40(14):2135-42 [15341989.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Biochem Biophys Res Commun. 1984 Aug 16;122(3):1450-9 [6477569.001]
  • [Cites] Nature. 1989 Nov 23;342(6248):440-3 [2531289.001]
  • [Cites] Oncogene. 1991 Nov;6(11):1997-2003 [1719465.001]
  • [Cites] Histopathology. 1992 Dec;21(6):591-4 [1361482.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1233-8 [8443802.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):169-80 [8534865.001]
  • [Cites] Int J Cancer. 1996 Jul 17;67(2):289-93 [8760601.001]
  • [Cites] Surg Oncol. 1996 Feb;5(1):15-21 [8837300.001]
  • [Cites] Cancer Gene Ther. 1996 Nov-Dec;3(6):393-404 [8988842.001]
  • [Cites] Br J Cancer. 1997;75(2):241-50 [9010033.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3305-13 [9242465.001]
  • [Cites] Biol Reprod. 1997 Oct;57(4):936-42 [9314600.001]
  • [Cites] J Surg Oncol. 1998 Mar;67(3):194-202 [9530893.001]
  • (PMID = 17461494.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HGF protein, human; 67256-21-7 / Hepatocyte Growth Factor
  • [Other-IDs] NLM/ PMC4146970
  •  go-up   go-down


3. Subramanian IV, Bui Nguyen TM, Truskinovsky AM, Tolar J, Blazar BR, Ramakrishnan S: Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival. Cancer Res; 2006 Apr 15;66(8):4319-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival.
  • A human ovarian cancer cell line, which migrates to mouse ovaries and establishes peritoneal carcinomatosis, was used to evaluate the cooperative effect of an antiangiogenic gene therapy combined with chemotherapy.
  • Both external and internal imaging, along with histopathology, showed migration of i.p. injected human ovarian cancer cell line to mouse ovaries.
  • Using this model, we evaluated the effect of adeno-associated virus (AAV)-mediated expression of a mutant endostatin either alone or in combination with carboplatin treatment.
  • Antiangiogenic gene therapy inhibited orthotopic growth of ovarian cancer and resulted in 33% long-term tumor-free survival.
  • A single cycle of carboplatin treatment combined with mutant endostatin gene therapy resulted in 60% of the animals remaining tumor free for >200 days, which was significantly better than rAAV-LacZ and/or carboplatin.
  • Combination treatment delayed tumor appearance in 40% of the animals, wherein the residual tumors were smaller in size with limited or no peritoneal metastasis.
  • These studies suggest that AAV-mediated gene therapy of P125A-endostatin in combination with carboplatin is a useful method to inhibit peritoneal dissemination of ovarian carcinoma.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618757.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA114340; United States / NIDA NIH HHS / DA / DA 11806
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Endostatins; BG3F62OND5 / Carboplatin
  •  go-up   go-down


Advertisement
4. Chakraborty G, Jain S, Patil TV, Kundu GC: Down-regulation of osteopontin attenuates breast tumour progression in vivo. J Cell Mol Med; 2008 Dec;12(6A):2305-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Elevated expression of osteopontin (OPN) in higher grades of breast carcinoma correlates with enhanced expressions of several oncogenic molecules (urokinase-type plasminogen activator [uPA], matrix metalloproteinase-2/-9 [MMP-2 and -9]) and increased angiogenic potential of breast carcinoma.
  • Moreover our results demonstrated that OPN-/- mice showed slower progression of tumour growth in breast cancer model as compared to wild-type mice.
  • Furthermore, the data showed that injection of carcinogenic compound, pristane (2, 6,10,14-tetramethylpen-tadecane) induces breast tumour progression leading to enhanced expression of OPN and other oncogenic molecules in mammary fat pad of nude- and wild-type mice but not in OPN-/- mice.
  • Our data revealed that knocking down of OPN effectively curb breast cancer progression and further suggested that developing of OPN-based therapeutics might be an emerging approach for the next generation of breast cancer management.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / therapy. Osteopontin / genetics
  • [MeSH-minor] Animals. Base Sequence. Cell Line, Tumor. Cell Movement. Down-Regulation. Female. Humans. Mammary Neoplasms, Experimental / chemically induced. Mammary Neoplasms, Experimental / genetics. Mammary Neoplasms, Experimental / metabolism. Mammary Neoplasms, Experimental / therapy. Matrix Metalloproteinases / genetics. Mice. Mice, Inbred C57BL. Mice, Knockout. Mice, Nude. NF-kappa B / genetics. Neoplasm Transplantation. Neovascularization, Pathologic. RNA Interference. RNA, Small Interfering / genetics. Terpenes / toxicity. Transplantation, Heterologous. Urokinase-Type Plasminogen Activator / genetics. von Willebrand Factor / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cell Mol Med. 2008 Aug;12(4):1420 [18419794.001]
  • (PMID = 18266970.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / RNA, Small Interfering; 0 / Spp1 protein, mouse; 0 / Terpenes; 0 / von Willebrand Factor; 106441-73-0 / Osteopontin; 26HZV48DT1 / pristane; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC4514110
  •  go-up   go-down


5. Li Z, Mahesh SP, Shen DF, Liu B, Siu WO, Hwang FS, Wang QC, Chan CC, Pastan I, Nussenblatt RB: Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma. Cancer Res; 2006 Nov 1;66(21):10586-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human primary intraocular lymphoma (PIOL) is predominantly a B cell-originated malignant disease with no appropriate animal models and effective therapies available.
  • This study aimed to establish a mouse model to closely mimic human B-cell PIOL and to test the therapeutic potential of a recently developed immunotoxin targeting human B-cell lymphomas.
  • The resemblance of this tumor model to human PIOL was examined by fundoscopy, histopathology, immunohistochemistry, and evaluated for molecular markers.
  • The therapeutic effectiveness of immunotoxin HA22 was tested by injecting the drug intravitreally.
  • This model may be a valuable tool in understanding the molecular pathogenesis of human PIOL and for the evaluation of new therapeutic approaches.
  • The results of B cell-specific immunotoxin therapy may have clinical implications in treating human PIOL.
  • [MeSH-major] B-Lymphocytes / drug effects. Eye Neoplasms / therapy. Immunotoxins / therapeutic use. Lymphoma, B-Cell / therapy

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1997 Jun 15;79(12):2409-13 [9191531.001]
  • [Cites] Arch Ophthalmol. 1997 Sep;115(9):1157-60 [9298057.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1545-50 [15746059.001]
  • [Cites] J Neuroophthalmol. 2005 Mar;25(1):33-6 [15756131.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):739-49, viii [16083834.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1476-87 [10778980.001]
  • [Cites] Curr Opin Oncol. 2001 May;13(3):137-42 [11307054.001]
  • [Cites] N Engl J Med. 2001 Jul 26;345(4):241-7 [11474661.001]
  • [Cites] Vision Res. 2002 Feb;42(4):487-95 [11853765.001]
  • [Cites] Curr Mol Med. 2001 May;1(2):259-72 [11899075.001]
  • [Cites] J Leukoc Biol. 2002 Jul;72(1):1-8 [12101256.001]
  • [Cites] Cancer. 2002 Jul 1;95(1):193-202 [12115333.001]
  • [Cites] Curr Opin Ophthalmol. 2002 Dec;13(6):411-8 [12441846.001]
  • [Cites] Blood. 2003 Feb 1;101(3):815-21 [12393412.001]
  • [Cites] Ophthalmology. 2003 Feb;110(2):421-6 [12578791.001]
  • [Cites] Methods Mol Biol. 2004;248:503-18 [14970517.001]
  • [Cites] Trans Am Ophthalmol Soc. 2003;101:275-92 [14971583.001]
  • [Cites] Ocul Immunol Inflamm. 2004 Mar;12(1):7-16 [15209459.001]
  • [Cites] J Leukoc Biol. 2004 Aug;76(2):462-71 [15155773.001]
  • [Cites] Can J Ophthalmol. 1986 Jun;21(4):144-9 [3755372.001]
  • [Cites] Ophthalmology. 1988 May;95(5):625-30 [3050698.001]
  • [Cites] Cancer. 1988 Dec 1;62(11):2461-5 [3179963.001]
  • [Cites] Science. 1991 Nov 22;254(5035):1173-7 [1683495.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):843-9 [8334638.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2462-3 [10476821.001]
  • [Cites] Ophthalmology. 1999 Sep;106(9):1805-10 [10485554.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2311-5 [10499598.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2004 Nov;242(11):901-13 [15565454.001]
  • [Cites] Curr Oncol Rep. 2005 Jan;7(1):74-9 [15610690.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Feb;46(2):415-9 [15671263.001]
  • [Cites] J Biol Chem. 1994 Jul 15;269(28):18327-31 [7913461.001]
  • [Cites] Recent Results Cancer Res. 1994;135:155-69 [8047690.001]
  • [Cites] J Natl Cancer Inst. 1996 May 15;88(10):675-9 [8627644.001]
  • [Cites] Br J Ophthalmol. 1997 Jan;81(1):31-6 [9135405.001]
  • (PMID = 17079483.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 EY000222-22
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CD22 protein, human; 0 / CXCR5 protein, human; 0 / Immunotoxins; 0 / Receptors, CXCR4; 0 / Receptors, CXCR5; 0 / Receptors, Chemokine; 0 / Sialic Acid Binding Ig-like Lectin 2
  • [Other-IDs] NLM/ NIHMS22190; NLM/ PMC1931503
  •  go-up   go-down


6. Di Nicolantonio F, Knight LA, Glaysher S, Whitehouse PA, Mercer SJ, Sharma S, Mills L, Prin A, Johnson P, Charlton PA, Norris D, Cree IA: Ex vivo reversal of chemoresistance by tariquidar (XR9576). Anticancer Drugs; 2004 Oct;15(9):861-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of P-glycoprotein (P-gp) has been demonstrated to confer resistance to several anticancer drugs, including anthracyclines, taxanes and vinca alkaloids.
  • Tariquidar is a novel inhibitor of P-gp that has been shown to reverse resistance to cytotoxic drugs in tumor cell lines and mouse xenografts.
  • We have used an ATP-based chemosensitivity assay (ATP-TCA) to compare the activity of cytotoxic drugs in combination with tariquidar against a variety of solid tumors (n = 37).
  • The results show that tariquidar is able to decrease resistance in a number of solid tumors resistant to cytotoxic drugs known to be P-gp substrates.
  • These data support the introduction of tariquidar in combination with chemotherapy to clinical trials of patients expressing P-gp.
  • [MeSH-major] Drug Resistance, Neoplasm / drug effects. Quinolines / pharmacology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Female. Humans. Male. Middle Aged. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. P-Glycoprotein / metabolism. Skin Neoplasms / drug therapy. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15457126.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / Quinolines; J58862DTVD / tariquidar
  •  go-up   go-down


7. Poikonen P, Sjöström J, Amini RM, Villman K, Ahlgren J, Blomqvist C: Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer. Br J Cancer; 2005 Sep 5;93(5):515-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer.
  • We wanted to study cyclin A as a marker for prognosis and chemotherapy response.
  • The proportion of cells expressing cyclin A was determined by immunohistochemistry using a mouse monoclonal antibody to human cyclin A.
  • A high cyclin A correlated significantly to a shorter time to first relapse, risk ratio (RR) 1.94 (95% CI 1.24-3.03) and survival from diagnosis, RR 2.49 (95% CI 1.45-4.29), cutoff point for high/low proliferation group 10.5%.
  • Cyclin A did not correlate to chemotherapy response or survival after anthracycline, docetaxel or MF therapy.
  • In the present study, cyclin A did not predict chemotherapy response.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Breast Neoplasms / drug therapy. Cyclin A / metabolism
  • [MeSH-minor] Carcinoma, Ductal / diagnosis. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / metabolism. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / metabolism. Fluorouracil / administration & dosage. Humans. Immunoenzyme Techniques. Methotrexate / administration & dosage. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Nov;81(6):1017-21 [10576659.001]
  • [Cites] Lancet. 1998 Sep 19;352(9132):930-42 [9752815.001]
  • [Cites] Acta Oncol. 2000;39(1):41-5 [10752652.001]
  • [Cites] Int J Cancer. 2001 Jul 15;93(2):283-7 [11410878.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):402-8 [11875707.001]
  • [Cites] Acta Oncol. 2002;41(4):334-45 [12234024.001]
  • [Cites] Lancet Oncol. 2002 Dec;3(12):719-27 [12473512.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1376-86 [12627500.001]
  • [Cites] J Pathol. 2003 Apr;199(4):424-31 [12635132.001]
  • [Cites] Int J Cancer. 2003 Jul 10;105(5):674-80 [12740917.001]
  • [Cites] J Clin Pathol. 2004 Jul;57(7):675-81 [15220356.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Feb 14;182(3):1144-54 [1531751.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2167-75 [7931487.001]
  • [Cites] Br J Cancer. 1994 Dec;70(6):1258-62 [7981085.001]
  • [Cites] Oncogene. 1997 Mar 13;14(10):1191-200 [9121768.001]
  • [Cites] Br J Cancer. 1997;75(12):1774-8 [9192980.001]
  • [Cites] Melanoma Res. 1997 Aug;7(4):329-34 [9293483.001]
  • [Cites] Anticancer Res. 1998 Jan-Feb;18(1B):571-6 [9568179.001]
  • [Cites] Eur J Cancer. 1999 Aug;35(8):1194-201 [10615229.001]
  • (PMID = 16091759.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin A; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2361595
  •  go-up   go-down


8. Bandapalli OR, Kahlert C, Hellstern V, Galindo L, Schirmacher P, Weitz J, Brand K: Cross-species comparison of biological themes and underlying genes on a global gene expression scale in a mouse model of colorectal liver metastasis and in clinical specimens. BMC Genomics; 2008;9:448
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cross-species comparison of biological themes and underlying genes on a global gene expression scale in a mouse model of colorectal liver metastasis and in clinical specimens.
  • BACKGROUND: Invasion-related genes over-expressed by tumor cells as well as by reacting host cells represent promising drug targets for anti-cancer therapy.
  • Generally, histopathology and gene expression correlated well as the highest single gene overlap was found to be 44% in syn-compartmental comparisons (liver versus liver) whereas cross-compartmental overlaps were much lower (e.g. liver versus tumor: 9.7%).
  • [MeSH-major] Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Gene Expression Regulation, Neoplastic. Liver Neoplasms / genetics. Liver Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Genome Biol. 2004;5(5):R34 [15128448.001]
  • [Cites] BMC Genomics. 2004 Aug 20;5(1):58 [15318950.001]
  • [Cites] Cancer Res. 1980 Jul;40(7):2142-6 [6992981.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):839-49 [15516957.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):48-55 [15608639.001]
  • [Cites] Stem Cells. 2005 Feb;23(2):166-85 [15671141.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2171-80 [15928670.001]
  • [Cites] BMC Bioinformatics. 2005;6 Suppl 2:S6 [16026603.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):74-89 [16080196.001]
  • [Cites] Genome Biol. 2005;6(13):R109 [16420669.001]
  • [Cites] PLoS Genet. 2007 Apr 20;3(4):e59 [17447843.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6844-53 [17638895.001]
  • [Cites] Int J Cancer. 2007 Nov 1;121(9):1941-8 [17631641.001]
  • [Cites] Br J Cancer. 2007 Nov 19;97(10):1432-40 [17940512.001]
  • [Cites] Nucleic Acids Res. 2005;33(1):272-9 [15647509.001]
  • (PMID = 18823562.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2573898
  •  go-up   go-down


9. Huang GW, Yang LY: Metallothionein expression in hepatocellular carcinoma. World J Gastroenterol; 2002 Aug;8(4):650-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Histological specimens of 35 cases of primary human hepatocellular carcinoma with para-neoplastic liver tissue and 5 cases of normal liver were stained for MTs with monoclonal mouse anti-MTs serum (E9) by the immunohistochemical ABC technique.
  • But MTs were stained strongly positive in all the five cases of normal liver and 35 cases of para-neoplastic liver tissue.
  • The differences of MTs expression between HCC and normal liver tissue or para-neoplastic liver tissue were highly significant (P<0.01).
  • We can choose the anticancer agents according to the MTs concentration in HCC, which may improve the results of chemotherapy for HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / enzymology. Liver Neoplasms / enzymology. Metallothionein / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174372.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 9038-94-2 / Metallothionein
  • [Other-IDs] NLM/ PMC4656314
  •  go-up   go-down


10. Isayeva T, Ren C, Ponnazhagan S: Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway. Gene Ther; 2007 Jan;14(2):138-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway.
  • Despite improvements from cytoreductive surgery and chemotherapy, recurrent disease remains a formidable challenge.
  • In the present study, we demonstrate for the first time that stable intra-abdominal genetic transfer of endostatin and angiostatin (E+A) by recombinant adeno-associated virus (rAAV) provides sustained antitumor effects on the growth and dissemination of epithelial ovarian cancer in a mouse model.
  • Further, when combined with paclitaxel (taxol), the effect of this therapy was dramatically increased and resulted in long-term tumor-free survival overcoming prior limitations of chemotherapy and gene therapy.
  • The combined effects of angiosuppressive therapy and chemotherapy were found to be independently of survivin pathway.
  • Evidence for the superior effects of the combination therapy was indicated by significantly lower ascites volume with less hemorrhage and tumor conglomerates, lower ascites vascular endothelial growth factor, higher tumor cell apoptosis and decreased blood vasculature, and long-term disease-free survival.
  • Histopathology of visceral organs and liver enzyme assays indicated no toxicity or pathology.
  • [MeSH-major] Angiogenesis Inhibitors / genetics. Dependovirus / genetics. Genetic Therapy / methods. Genetic Vectors / administration & dosage. Neoplasm Recurrence, Local / therapy. Ovarian Neoplasms / therapy
  • [MeSH-minor] Angiostatins / genetics. Angiostatins / therapeutic use. Animals. Antineoplastic Agents / therapeutic use. Ascitic Fluid / drug effects. Combined Modality Therapy. Drug Resistance, Neoplasm. Endostatins / genetics. Endostatins / therapeutic use. Female. Gene Expression. Inhibitor of Apoptosis Proteins. Injections, Intraperitoneal. Mice. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Paclitaxel / therapeutic use. Signal Transduction / physiology. Survival Rate. Vascular Endothelial Growth Factor A / analysis. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16943851.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA90850; United States / NCI NIH HHS / CA / R01CA98817
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / BIRC5 protein, human; 0 / Endostatins; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Vascular Endothelial Growth Factor A; 86090-08-6 / Angiostatins; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


11. Mattheolabakis G, Taoufik E, Haralambous S, Roberts ML, Avgoustakis K: In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles. Eur J Pharm Biopharm; 2009 Feb;71(2):190-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Normal BALB/c mice tolerated three weekly intravenous injections of a relatively high dose of blank PLGA-mPEG nanoparticles (500 mg/kg, equivalent to about 10mg nanoparticles/mouse) and three weekly intravenous injections of a high dose of nanoparticle-entrapped cisplatin (10 mg/kg).
  • Also, histopathology examination indicated that there were no differences in the kidneys or spleens from animals treated with cisplatin-loaded nanoparticles or blank nanoparticles compared to the untreated control group.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cisplatin / pharmacology. Colorectal Neoplasms / drug therapy. Nanoparticles
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Animals. Dose-Response Relationship, Drug. Drug Carriers / chemistry. Female. HT29 Cells. Humans. Injections, Intravenous. Male. Mice. Mice, Inbred BALB C. Mice, SCID. Polyethylene Glycols / chemistry. Polyglactin 910 / chemistry. Survival Rate. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18929649.001).
  • [ISSN] 1873-3441
  • [Journal-full-title] European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V
  • [ISO-abbreviation] Eur J Pharm Biopharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / poly(D,L-lactic-co-glycolic acid)-methoxy-poly(ethyleneglycol) copolymer; 30IQX730WE / Polyethylene Glycols; 34346-01-5 / Polyglactin 910; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Li J, Chigurupati S, Agarwal R, Mughal MR, Mattson MP, Becker KG, Wood WH 3rd, Zhang Y, Morin PJ: Possible angiogenic roles for claudin-4 in ovarian cancer. Cancer Biol Ther; 2009 Oct;8(19):1806-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, an in vivo mouse dorsal skinfold assay confirms that cells expressing claudin-4 secrete factors that can mediate angiogenesis in the dorsal skin of mice.
  • [MeSH-major] Membrane Proteins / biosynthesis. Ovarian Neoplasms / blood supply

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1980 May 2;208(4443):516-8 [6154315.001]
  • [Cites] Mol Biol Cell. 2007 Dec;18(12):5014-23 [17928406.001]
  • [Cites] J Natl Cancer Inst. 1989 Apr 5;81(7):497-502 [2921774.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6553-60 [1384965.001]
  • [Cites] Science. 1992 Dec 11;258(5089):1798-801 [1281554.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1055-62 [7692730.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2778-84 [8168110.001]
  • [Cites] Lab Invest. 1994 Oct;71(4):510-8 [7967506.001]
  • [Cites] J Biol Chem. 1995 Nov 10;270(45):27348-57 [7592998.001]
  • [Cites] J Clin Invest. 1996 Jun 15;97(12):2792-802 [8675690.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):808-14 [9485039.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1998 Sep;34(8):636-9 [9769148.001]
  • [Cites] Pathobiology. 1999;67(1):12-8 [9873223.001]
  • [Cites] J Clin Invest. 1999 May;103(9):1237-41 [10225966.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):481-95 [15563311.001]
  • [Cites] Hum Pathol. 2005 Feb;36(2):162-9 [15754293.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1765-76 [15965503.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7378-85 [16103090.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8519-29 [16166333.001]
  • [Cites] Cell Cycle. 2005 Aug;4(8):1033-5 [16082202.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9603-6 [16266975.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1884-91 [16287068.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):995-1005 [18195328.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 5;100(5):359-72 [18314475.001]
  • [Cites] Oncol Rep. 2008 Apr;19(4):953-9 [18357381.001]
  • [Cites] Hum Pathol. 2008 May;39(5):747-57 [18439941.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):263-9 [18313739.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6735-41 [18980965.001]
  • [Cites] J Interferon Cytokine Res. 2008 Dec;28(12):733-40 [18937547.001]
  • [Cites] Mod Pathol. 2008 Nov;21(11):1320-9 [18587324.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4932-8 [10987309.001]
  • [Cites] FASEB J. 2000 Oct;14(13):2055-64 [11023990.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):5269-77 [11046061.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Histopathology. 2001 Feb;38(2):87-95 [11207821.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Apr;2(4):285-93 [11283726.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28204-11 [11382769.001]
  • [Cites] Cytokine Growth Factor Rev. 2001 Dec;12(4):375-91 [11544106.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):125-34 [12107097.001]
  • [Cites] Curr Oncol Rep. 2002 Nov;4(6):510-4 [12354364.001]
  • [Cites] J Mol Diagn. 2003 May;5(2):73-81 [12707371.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2567-75 [12855632.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6265-71 [14559813.001]
  • [Cites] J Immunol. 2003 Dec 15;171(12):6714-22 [14662875.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3291-300 [15161682.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4427-36 [15240533.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):397-414 [15277215.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):14-25 [15305371.001]
  • [Cites] Hum Pathol. 2006 May;37(5):569-77 [16647955.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5251-7 [16707450.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):405-16 [16725184.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Nat Rev Drug Discov. 2007 Apr;6(4):273-86 [17396134.001]
  • [Cites] Oncogene. 2007 May 31;26(26):3846-56 [17160014.001]
  • [Cites] Histol Histopathol. 2007 Nov;22(11):1185-95 [17647191.001]
  • [Cites] Cancer Res. 1987 Oct 1;47(19):5155-61 [2441862.001]
  • (PMID = 19657234.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 AG000395-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLDN4 protein, human; 0 / Claudin-4; 0 / Cldn4 protein, mouse; 0 / Membrane Proteins
  • [Other-IDs] NLM/ NIHMS137709; NLM/ PMC2795001
  •  go-up   go-down


13. Thewes V, Orso F, Jäger R, Eckert D, Schäfer S, Kirfel G, Garbe S, Taverna D, Schorle H: Interference with activator protein-2 transcription factors leads to induction of apoptosis and an increase in chemo- and radiation-sensitivity in breast cancer cells. BMC Cancer; 2010;10:192
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By using information obtained from Ingenuity Pathway Analysis Systems we were able to present proven or potential connections between AP-2 regulated genes involved in cell death and response to chemo- and radiation therapy, (i.e.
  • Therefore, interference with AP-2 function could increase the sensitivity of tumor cells towards therapeutic intervention.
  • [MeSH-major] Apoptosis. Drug Resistance, Neoplasm. Mammary Neoplasms, Experimental / metabolism. Radiation Tolerance. Transcription Factor AP-2 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene. 2000 Dec 30;260(1-2):1-12 [11137286.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Feb;30(2):113-22 [11135428.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jan;71(1):47-57 [11859873.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45028-33 [12226108.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):214-20 [12610102.001]
  • [Cites] Dev Biol. 2003 Apr 1;256(1):127-45 [12654297.001]
  • [Cites] Mol Cancer Res. 2003 Oct;1(12):921-9 [14573793.001]
  • [Cites] Clin Ter. 2003 Sep-Oct;154(5):325-35 [14994922.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11432-7 [15273288.001]
  • [Cites] Science. 1991 Mar 1;251(4997):1067-71 [1998122.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2156-60 [8134364.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4257-60 [8044767.001]
  • [Cites] Genomics. 1996 Jul 1;35(1):262-4 [8661133.001]
  • [Cites] Crit Rev Biochem Mol Biol. 1995;30(6):445-600 [8770536.001]
  • [Cites] Oncogene. 1996 Oct 17;13(8):1701-7 [8895516.001]
  • [Cites] Nat Genet. 1997 Jan;15(1):78-82 [8988173.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):781-91 [15613452.001]
  • [Cites] Mod Pathol. 2005 Mar;18(3):431-8 [15467710.001]
  • [Cites] Breast Cancer Res Treat. 2005 Apr;90(3):273-80 [15830141.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8628-34 [16204029.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Genome Biol. 2005;6(13):246 [16420676.001]
  • [Cites] J Comput Biol. 2006 May;13(4):996-1003 [16761924.001]
  • [Cites] J Biol Chem. 2006 Jun 16;281(24):16207-19 [16533807.001]
  • [Cites] Nephron Exp Nephrol. 2006;103(4):e166-74 [16636587.001]
  • [Cites] Int J Cancer. 2007 May 15;120(10):2061-7 [17330235.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6115-21 [17947476.001]
  • [Cites] Histopathology. 2007 Dec;51(6):814-23 [18042070.001]
  • [Cites] Cancer Res. 2008 Oct 15;68(20):8295-303 [18922901.001]
  • [Cites] J Pathol. 2009 Jan;217(1):32-41 [18825690.001]
  • [Cites] Mol Cancer Res. 2006 Aug;4(8):591-8 [16877704.001]
  • [Cites] Circulation. 1999 Nov 16;100(20):2108-12 [10562268.001]
  • [Cites] J Pathol. 1999 Dec;189(4):514-20 [10629551.001]
  • [Cites] Eur J Pharmacol. 2000 Mar 24;392(1-2):19-22 [10748267.001]
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):186-94 [10861472.001]
  • [Cites] Life Sci. 2001 Sep 21;69(18):2157-65 [11669459.001]
  • (PMID = 20459791.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Isoforms; 0 / Transcription Factor AP-2; EC 2.7.10.1 / Erbb2 protein, mouse; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2890516
  •  go-up   go-down


14. Farinelle S, Malonne H, Chaboteaux C, Decaestecker C, Dedecker R, Gras T, Darro F, Fontaine J, Atassi G, Kiss R: Characterization of TNP-470-induced modifications to cell functions in HUVEC and cancer cells. J Pharmacol Toxicol Methods; 2000 Jan-Feb;43(1):15-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The in vitro effects were characterized on the mouse mammary MXT adenocarcinoma, on which we also characterized the influence of three clinically active anti-tumor compounds (as cytotoxic references).
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Antibiotics, Antineoplastic / pharmacology. Endothelium, Vascular / drug effects. Mammary Neoplasms, Experimental / blood supply. Mammary Neoplasms, Experimental / drug therapy. Sesquiterpenes / pharmacology
  • [MeSH-minor] Adenocarcinoma / blood supply. Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Animals. Biocompatible Materials. Cell Division / drug effects. Cell Movement / drug effects. Collagen. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Cyclohexanes. Drug Combinations. Glioblastoma / drug therapy. Glioblastoma / pathology. Growth Inhibitors / pharmacology. Growth Inhibitors / toxicity. Humans. Laminin. Mice. Neoplasm Transplantation. Neovascularization, Pathologic / drug therapy. Paclitaxel / pharmacology. Paclitaxel / toxicity. Proteoglycans. Tumor Cells, Cultured / drug effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11091126.001).
  • [ISSN] 1056-8719
  • [Journal-full-title] Journal of pharmacological and toxicological methods
  • [ISO-abbreviation] J Pharmacol Toxicol Methods
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibiotics, Antineoplastic; 0 / Biocompatible Materials; 0 / Cyclohexanes; 0 / Drug Combinations; 0 / Growth Inhibitors; 0 / Laminin; 0 / Proteoglycans; 0 / Sesquiterpenes; 119978-18-6 / matrigel; 129298-91-5 / O-(chloroacetylcarbamoyl)fumagillol; 9007-34-5 / Collagen; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


15. Hausner SH, Abbey CK, Bold RJ, Gagnon MK, Marik J, Marshall JF, Stanecki CE, Sutcliffe JL: Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model. Cancer Res; 2009 Jul 15;69(14):5843-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cell surface receptor alpha(v)beta(6) is epithelial specific, and its expression is tightly regulated; it is low or undetectable in adult tissues but has been shown to be increased in many different cancers, including pancreatic, cervical, lung, and colon cancers.
  • We have recently shown the feasibility of imaging alpha(v)beta(6) in vivo by positron emission tomography (PET) using the peptide [(18)F]FBA-A20FMDV2.
  • Here, we describe improved alpha(v)beta(6) imaging agents and test their efficacy in a mouse model with endogenous alpha(v)beta(6) expression.
  • Pancreatic ductal adenocarcinoma is highly metastatic and current preoperative evaluation of resectability using noninvasive imaging has limited success, with most patients having metastases at time of surgery.
  • The fact that these tumors express alpha(v)beta(6) suggests that this probe has significant potential for the in vivo detection of this malignancy, thus having important implications for patient care and therapy.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2005 Aug;46(8):1333-41 [16085591.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):235-43 [16041214.001]
  • [Cites] J Oral Pathol Med. 2006 Jan;35(1):1-10 [16393247.001]
  • [Cites] Mol Pharm. 2006 Sep-Oct;3(5):472-87 [17009846.001]
  • [Cites] J Nucl Med. 2007 Jan;48 Suppl 1:4S-18S [17204716.001]
  • [Cites] J Nucl Med. 2007 Jan;48 Suppl 1:78S-88S [17204723.001]
  • [Cites] Radiology. 2007 Feb;242(2):360-85 [17255408.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] J Pathol. 2007 Jul;212(3):316-24 [17503414.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5889-95 [17575158.001]
  • [Cites] Cancer Res. 2007 Aug 15;67(16):7833-40 [17699789.001]
  • [Cites] Cancer Invest. 2007 Oct;25(7):632-46 [18027153.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):561-70 [18199553.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2008 Feb;20(1):61-6 [17981018.001]
  • [Cites] Am J Pathol. 2008 May;172(5):1271-86 [18385522.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(4):429-35 [18670846.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6351-3 [18927272.001]
  • [Cites] J Nucl Med. 2000 Mar;41(3):429-38 [10716315.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):641-50 [11340566.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Feb 10;55(2):217-50 [12564978.001]
  • [Cites] Nat Rev Drug Discov. 2003 Mar;2(3):214-21 [12612647.001]
  • [Cites] Nat Rev Drug Discov. 2003 May;2(5):347-60 [12750738.001]
  • [Cites] Semin Nucl Med. 2004 Jan;34(1):56-69 [14735459.001]
  • [Cites] Histopathology. 2004 Sep;45(3):226-36 [15330800.001]
  • [Cites] J Biol Chem. 1990 Jul 15;265(20):11502-7 [2365683.001]
  • [Cites] Radiology. 1993 Dec;189(3):847-50 [8234714.001]
  • [Cites] J Histochem Cytochem. 1993 Oct;41(10):1521-7 [8245410.001]
  • [Cites] J Cell Sci. 1995 Jun;108 ( Pt 6):2241-51 [7673344.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1565-70 [9843289.001]
  • [Cites] Ann Surg. 1999 May;229(5):729-37; discussion 737-8 [10235532.001]
  • [Cites] J Clin Invest. 2005 Feb;115(2):339-47 [15668738.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(1):4-10 [15747028.001]
  • [Cites] Cancer Metastasis Rev. 2005 Sep;24(3):395-402 [16258727.001]
  • (PMID = 19549907.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA107792-02; United States / NCI NIH HHS / CA / R21 CA107792; United States / NCI NIH HHS / CA / R21 CA107792-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Benzoates; 0 / Fluorine Radioisotopes; 0 / Integrins; 0 / Radiopharmaceuticals; 0 / Viral Proteins; 0 / integrin alphavbeta6; V5ROO2HOU4 / 4-fluorobenzoic acid
  • [Other-IDs] NLM/ NIHMS117292; NLM/ PMC2711989
  •  go-up   go-down


16. Banerjee S, Choi M, Aboukameel A, Wang Z, Mohammad M, Chen J, Yang D, Sarkar FH, Mohammad RM: Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells. Pancreas; 2010 Apr;39(3):323-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Overexpression of antiapoptotic Bcl-2 family proteins confers resistance to conventional therapy in pancreatic cancer patients.
  • In vivo efficacy of ApoG2 was evaluated in a xenograft model to confirm its therapeutic benefit with gemcitabine.
  • Furthermore, administration of ApoG2 with gemcitabine resulted in a statistically higher antitumor activity compared with either ApoG2 or gemcitabine alone in a severe combined immunodeficiency mouse xenograft model.
  • CONCLUSIONS: Apogossypolone, which functions as a potent pan-Bcl-2 family inhibitor, seems therapeutically promising for future translational studies including the treatment of pancreatic cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Deoxycytidine / analogs & derivatives. Gossypol / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors
  • [MeSH-minor] Animals. Apoptosis / drug effects. Apoptosis Regulatory Proteins / antagonists & inhibitors. Cell Line, Tumor. Drug Resistance, Neoplasm. Drug Synergism. Female. Humans. Membrane Proteins / antagonists & inhibitors. Mice. Mice, SCID. Myeloid Cell Leukemia Sequence 1 Protein. Proto-Oncogene Proteins / antagonists & inhibitors. Xenograft Model Antitumor Assays. bcl-2-Associated X Protein / antagonists & inhibitors

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • Genetic Alliance. consumer health - Pancreatic cancer 2.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Gossypol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1498-502 [10749111.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Surg Oncol. 2001 Mar;76(3):188-96 [11276023.001]
  • [Cites] Pancreas. 2001 Apr;22(3):230-9 [11291923.001]
  • [Cites] Science. 2001 Apr 27;292(5517):727-30 [11326099.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1122-9 [11571724.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(1):1-11 [12021893.001]
  • [Cites] Pancreatology. 2001;1(3):254-62 [12120204.001]
  • [Cites] J Med Chem. 2003 Sep 25;46(20):4259-64 [13678404.001]
  • [Cites] Cell. 2004 Jan 23;116(2):205-19 [14744432.001]
  • [Cites] Int J Cancer. 2004 Mar 20;109(2):182-8 [14750167.001]
  • [Cites] Science. 2004 Feb 13;303(5660):1010-4 [14963330.001]
  • [Cites] Chem Biol. 2004 Mar;11(3):389-95 [15123268.001]
  • [Cites] Science. 2004 Jul 30;305(5684):626-9 [15286356.001]
  • [Cites] Surgery. 2004 Aug;136(2):443-8 [15300213.001]
  • [Cites] Mol Cell Biol. 1997 Dec;17(12):7040-6 [9372935.001]
  • [Cites] Trends Cell Biol. 1998 Aug;8(8):324-30 [9704409.001]
  • [Cites] Histopathology. 1998 Nov;33(5):432-9 [9839167.001]
  • [Cites] Ann Surg. 1998 Dec;228(6):780-7 [9860477.001]
  • [Cites] Gut. 1998 Sep;43(3):414-21 [9863489.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):13-21 [15657349.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Blood. 2005 Jul 15;106(2):408-18 [15797997.001]
  • [Cites] J Clin Invest. 2005 Oct;115(10):2648-55 [16200198.001]
  • [Cites] Eur J Cancer. 2005 Oct;41(15):2213-36 [16146690.001]
  • [Cites] Pancreas. 2005 Nov;31(4):317-24 [16258364.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1260-8 [16475211.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):906-17 [17131310.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Curr Opin Immunol. 2007 Oct;19(5):488-96 [17629468.001]
  • [Cites] Mol Cancer. 2008;7:20 [18275607.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3012-7 [11248023.001]
  • (PMID = 19823097.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109389; United States / NCI NIH HHS / CA / R01 CA109389
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Bcl-2-like protein 11; 0 / Mcl1 protein, mouse; 0 / Membrane Proteins; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / apogossypolone; 0 / bcl-2-Associated X Protein; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; KAV15B369O / Gossypol
  • [Other-IDs] NLM/ NIHMS512774; NLM/ PMC3807128
  •  go-up   go-down


17. McCallum M, Baker C, Gillespie K, Cohen B, Stewart H, Leonard R, Cameron D, Leake R, Paxton J, Robertson A, Purdie C, Gould A, Steel M: A prognostic index for operable, node-negative breast cancer. Br J Cancer; 2004 May 17;90(10):1933-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the case of molecular assays, sensitivity and reliability were compromised by the age of the tissue specimens and the variability of fixation protocols.
  • In selecting patients for adjuvant systemic chemotherapy, the proposed index improves considerably on current international guidelines and matches the performance reported for 'gene-expression signature' analysis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Lymphatic Metastasis. Muscle Proteins. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 1989 Dec;3(4):641-52 [2558104.001]
  • [Cites] Breast Cancer Res Treat. 1998;52(1-3):1-15 [10066068.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1102-4 [2045851.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Adv Cancer Res. 1993;61:25-56 [8346719.001]
  • [Cites] Biochim Biophys Acta. 1994 Dec 30;1198(2-3):113-30 [7819270.001]
  • [Cites] Nat Med. 1997 Feb;3(2):222-5 [9018243.001]
  • [Cites] Am J Epidemiol. 1997 Aug 15;146(4):307-14 [9270409.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):462-9 [9469329.001]
  • [Cites] Br J Cancer. 1998 Mar;77(5):789-96 [9514059.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2025-31 [9626199.001]
  • [Cites] Br J Cancer. 1998 May;77(9):1495-501 [9652768.001]
  • [Cites] Int J Cancer. 1999 Dec 22;84(6):562-7 [10567899.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):298-304 [10667580.001]
  • [Cites] Semin Oncol. 2001 Feb;28(1):53-67 [11254867.001]
  • [Cites] J Natl Cancer Inst. 2001 Mar 21;93(6):456-62 [11259471.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 4;93(13):979-89 [11438563.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3817-27 [11559719.001]
  • [Cites] Endocr Relat Cancer. 2001 Sep;8(3):259-63 [11566617.001]
  • [Cites] J Steroid Biochem Mol Biol. 2001 Nov;78(5):409-18 [11738551.001]
  • [Cites] Ann Surg. 2002 Jan;235(1):10-26 [11753038.001]
  • [Cites] Clin Lab Med. 2001 Dec;21(4):875-95, x [11770293.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):754-60 [11920647.001]
  • [Cites] Breast Cancer Res. 2002;4(3):R3 [12052255.001]
  • [Cites] Oncogene. 2002 Jul 11;21(30):4680-90 [12096344.001]
  • [Cites] N Engl J Med. 2002 Nov 14;347(20):1566-75 [12432043.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Semin Cancer Biol. 1999 Apr;9(2):125-38 [10202134.001]
  • [Cites] Dis Markers. 1998 Nov;14(3):165-7 [10427476.001]
  • [Cites] Br J Cancer. 1999 Aug;80(12):1968-73 [10471047.001]
  • [Cites] Cancer Causes Control. 1999 Oct;10(5):431-7 [10530614.001]
  • [Cites] Br J Cancer. 1957 Sep;11(3):359-77 [13499785.001]
  • [Cites] Nat Med. 2003 Jan;9(1):9 [12514705.001]
  • [Cites] Nat Med. 2003 Jan;9(1):16-8 [12514712.001]
  • [Cites] Ann N Y Acad Sci. 2002 Dec;975:217-31 [12538167.001]
  • [Cites] J Clin Oncol. 2003 Feb 1;21(3):458-62 [12560435.001]
  • [Cites] Breast Cancer Res Treat. 2003 Mar;78(1):45-50 [12611456.001]
  • [Cites] Breast Cancer Res. 2003;5(2):R30-6 [12631396.001]
  • [Cites] Lancet. 2003 Aug 2;362(9381):362-9 [12907009.001]
  • [Cites] Breast Cancer Res. 2003;5(6):R242-9 [14580260.001]
  • [Cites] Breast Cancer Res. 2004;6(1):R8-R17 [14680495.001]
  • [Cites] Adv Cancer Res. 1985;44:139-266 [2930999.001]
  • [Cites] Lancet. 1987 Jul 25;2(8552):171-5 [2885637.001]
  • [Cites] Cytometry. 1989 May;10(3):229-41 [2653738.001]
  • [Cites] Lancet. 1998 Sep 19;352(9132):930-42 [9752815.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6827-9 [2119883.001]
  • (PMID = 15138474.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Microfilament Proteins; 0 / Muscle Proteins; 0 / Tagln protein, mouse; 136601-57-5 / Cyclin D1
  • [Other-IDs] NLM/ PMC2409476
  •  go-up   go-down


18. Macor P, Secco E, Zorzet S, Tripodo C, Celeghini C, Tedesco F: An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies. Curr Pharm Des; 2008;14(21):2023-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies.
  • B-cell malignancies account for over the 90% of all lymphoid neoplasms.
  • The clonal proliferations of B-cells show a high degree of variation in terms of clinical and presenting features, histopathology, immunophenotype, and genetics.
  • The disadvantages of these models include the differences between rodent and human stroma and that they can not be used to characterise anti-tumor activity of many immunotherapeutic drugs.
  • These models can be used to study the molecular processes critical for the development, proliferation and survival of hematological malignancies and to characterise potential therapeutic targets.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Neoplasms, Experimental / metabolism. Xenograft Model Antitumor Assays / methods
  • [MeSH-minor] Animals. Drug Delivery Systems. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / metabolism. Mice. Multiple Myeloma / drug therapy. Multiple Myeloma / metabolism. Species Specificity

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18691113.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 195
  •  go-up   go-down


19. Nielsen LL, Gurnani M, Shi B, Terracina G, Johnson RC, Carroll J, Mathis JM, Hajian G: Derivation and initial characterization of a mouse mammary tumor cell line carrying the polyomavirus middle T antigen: utility in the development of novel cancer therapeutics. Cancer Res; 2000 Dec 15;60(24):7066-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Derivation and initial characterization of a mouse mammary tumor cell line carrying the polyomavirus middle T antigen: utility in the development of novel cancer therapeutics.
  • Here we describe the derivation of novel cell lines from spontaneous mammary tumors that arose in mouse mammary tumor virus-polyomavirus (MMTV-PyV) Middle T (MidT) transgenic mice.
  • Clonal cell lines from four mixed cell populations were tested for adenovirus transducibility and sensitivity to p53 tumor suppressor gene therapy mediated by SCH58500, a replication-deficient adenovirus that expresses human p53.
  • This cell line carried the PyV MidT antigen, had wild-type p53 DNA, and was sensitive to suppression of proliferation by MMAC/PTEN tumor suppressor gene therapy.
  • The histopathology of MidT2-1 tumors closely resembled the histopathology of the primary transgenic tumors.
  • Tumor growth in vivo was inhibited by p53 gene therapy or by MMAC gene therapy.
  • In addition, combination therapy with a number of anticancer agents had synergistic or additive efficacy in vitro.
  • In particular, MMAC gene therapy synergized with SCH58500 or paclitaxel. In the i.p.
  • MidT2-1 tumor model p53 gene therapy enhanced the survival benefits of paclitaxel/cisplatin chemotherapy.
  • Combination therapy has become a mainstay in cancer treatment.
  • In this report, we use a novel transgenic mouse tumor cell line to suggest new combinations that might be explored in clinical cancer care.
  • These include gene therapy using the tumor suppressors MMAC and p53, chemotherapy using farnesyl transferase inhibitors, the microtubule stabilizing taxanes, and the DNA synthesis disruptors gemcitabine and cisplatin.
  • The precise biological mechanisms by which these therapies induce their antitumor effects are not fully elucidated.
  • However, the work presented here suggests that many of these therapeutic approaches have synergistic antitumor activity when used in combination.
  • [MeSH-major] Antigens, Polyomavirus Transforming / metabolism. Mammary Neoplasms, Animal / immunology. Mammary Neoplasms, Animal / therapy. Protein-Serine-Threonine Kinases. Taxoids. Tumor Cells, Cultured. Tumor Suppressor Proteins
  • [MeSH-minor] Adenoviridae / genetics. Alkyl and Aryl Transferases / antagonists & inhibitors. Animals. Antineoplastic Agents / pharmacology. Antineoplastic Agents, Phytogenic / pharmacology. Blotting, Western. Bridged Compounds / pharmacology. Cell Division. Cisplatin / pharmacology. Deoxycytidine / analogs & derivatives. Deoxycytidine / pharmacology. Dose-Response Relationship, Drug. Farnesyltranstransferase. Female. Gene Transfer Techniques. Genes, p53 / genetics. Mice. Mice, Transgenic. Nucleic Acid Synthesis Inhibitors / pharmacology. PTEN Phosphohydrolase. Paclitaxel / pharmacology. Phosphoric Monoester Hydrolases / metabolism. Polymerase Chain Reaction. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-akt. Sequence Analysis, DNA. Time Factors. Transduction, Genetic. Tumor Suppressor Protein p53 / metabolism

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11156413.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Bridged Compounds; 0 / Nucleic Acid Synthesis Inhibitors; 0 / Proto-Oncogene Proteins; 0 / Taxoids; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0W860991D6 / Deoxycytidine; 1605-68-1 / taxane; B76N6SBZ8R / gemcitabine; EC 2.5.- / Alkyl and Aryl Transferases; EC 2.5.1.29 / Farnesyltranstransferase; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.3.67 / PTEN Phosphohydrolase; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Kline RP, Wu EX, Petrylak DP, Szabolcs M, Alderson PO, Weisfeldt ML, Cannon P, Katz J: Rapid in vivo monitoring of chemotherapeutic response using weighted sodium magnetic resonance imaging. Clin Cancer Res; 2000 Jun;6(6):2146-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A novel pulse sequence strategy uses sodium magnetic resonance imaging to monitor the response to chemotherapy of mouse xenograft tumors propagated from human prostate cancer cell lines.
  • An inversion pulse suppresses sodium with long longitudinal relaxation times, weighting the image toward intracellular sodium nuclei.
  • Experiments with these same drugs and cells, treated in culture, detected a significant intracellular sodium elevation (10-20 mM) using a ratiometric fluorescent dye.
  • Histopathology on formalin-fixed sections of explanted tumors confirmed that drug administration reduces proliferation (2.2 versus 8.6 mitotic figures per high power field; P < 0.0001), an effect that inversely correlates with the sodium magnetic resonance image response on a tumor-to-tumor basis (P < 0.02; n = 10).
  • Advantages of this sodium imaging technique include rapid determination of drug efficacy, improved diagnosis of lesions, ease of coregistration with high resolution proton magnetic resonance imaging, and absence of costly or toxic reagents.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Paclitaxel / analogs & derivatives. Prostatic Neoplasms / drug therapy. Sodium. Taxoids
  • [MeSH-minor] Animals. Annexin A5 / metabolism. Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis. Cell Nucleus / metabolism. Etoposide / pharmacology. Flow Cytometry. Fluorescent Antibody Technique. Fluorescent Dyes / pharmacology. Humans. Male. Mice. Neoplasm Transplantation / pathology. Phantoms, Imaging. Sodium Chloride / chemistry. Time Factors. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. SODIUM .
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10873063.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antineoplastic Agents, Phytogenic; 0 / Fluorescent Dyes; 0 / Taxoids; 15H5577CQD / docetaxel; 451W47IQ8X / Sodium Chloride; 6PLQ3CP4P3 / Etoposide; 9NEZ333N27 / Sodium; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


21. Hosotani R, Miyamoto Y, Fujimoto K, Doi R, Otaka A, Fujii N, Imamura M: Trojan p16 peptide suppresses pancreatic cancer growth and prolongs survival in mice. Clin Cancer Res; 2002 Apr;8(4):1271-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The tumor suppressor gene p16INK4A is inactivated frequently in a large number of human cancers, and many investigators have attempted to restore the function of p16 using the p16 wild-type gene and viral vectors.
  • EXPERIMENTAL DESIGN: Injections (i.p.) of the Trojan p16 peptide (100 microg/mouse/day) were given for 3 weeks in the AsPC-1 and BxPC-3 s.c. tumor models.
  • Tumor growth, histopathology, and TUNEL staining of the tumor and toxicity of the animals were evaluated.
  • RESULTS: In the AsPC-1 s.c. tumor model, a significant growth inhibition was obtained by the Trojan p16 treatment when compared with the three control treatments, i.e., vehicle, unconjugated form of p16, or Trojan peptide alone.
  • Histopathology of the BxPC-3 s.c. tumor in the Trojan p16 treatment group revealed marked vacuole formation and apoptotic death of cancer cells.
  • CONCLUSIONS: These results provide evidence that the Trojan p16 peptide system, a gene-oriented peptide coupled with a peptide vector, functions for experimental pancreatic cancer therapy.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / genetics. Pancreatic Neoplasms / drug therapy. Peptide Fragments / pharmacology
  • [MeSH-minor] Amino Acid Sequence. Animals. Blood Cell Count. Body Weight / drug effects. Cell Division / drug effects. Dose-Response Relationship, Drug. Humans. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Molecular Sequence Data. Neoplasm Transplantation. Survival Analysis. Survival Rate. Tumor Cells, Cultured / drug effects. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11948142.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Peptide Fragments
  •  go-up   go-down


22. Okaro AC, Fennell DA, Corbo M, Davidson BR, Cotter FE: Pk11195, a mitochondrial benzodiazepine receptor antagonist, reduces apoptosis threshold in Bcl-X(L) and Mcl-1 expressing human cholangiocarcinoma cells. Gut; 2002 Oct;51(4):556-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Cells growing in culture were used to perform in vitro experiments over 48-96 hours following treatment.
  • The cytotoxic agents used were 5 fluorouracil 10 microM and etoposide (Vp16) 10 microM, together with ultraviolet and 0.5-1 Gy x ray irradiation with or without 75 microM Pk11195.
  • Severe combined immunodeficient non-obese diabetic (SCID-NOD) mice with subcutaneous xenografts using the Egi-1 and Tfk-1 cell lines were treated with etoposide with or without addition of Pk11195 over a 72 hour period during which time the xenograft growth patterns were monitored.
  • RESULTS: In vitro, the effect of Pk11195 on induction of apoptosis in cholangiocarcinoma cells following stimulation by chemotherapy or radiotherapy was found to be both time and dose dependent, with Pk11195 increasing rates of apoptosis by 50-95%.
  • Intraperitoneal administration of Pk11195 in combination with Vp16 was found to increase the growth inhibiting effects of Vp16 on xenografts during the treatment phase.
  • CONCLUSION: This is the first study to demonstrate that functional antagonism of coexpressed Bcl-X(L) and Mcl-1 proteins using the mBzR antagonist Pk11195 can facilitate apoptosis in cholangiocarcinoma following chemotherapy and radiotherapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Cholangiocarcinoma / drug therapy. Isoquinolines / pharmacology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest New Drugs. 1999;17(1):57-62 [10555123.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]
  • [Cites] J Clin Pathol. 2001 Dec;54(12):927-32 [11729212.001]
  • [Cites] Br J Cancer. 1972 Aug;26(4):239-57 [4561027.001]
  • [Cites] Am Surg. 1981 Mar;47(3):99-102 [6163383.001]
  • [Cites] J Biol Chem. 1999 Apr 16;274(16):11245-52 [10196212.001]
  • [Cites] Exp Cell Res. 1999 Jun 15;249(2):413-21 [10366441.001]
  • [Cites] Histopathology. 1999 Jun;34(6):497-501 [10383693.001]
  • [Cites] Lancet. 1985 Nov 2;2(8462):990-3 [2414614.001]
  • [Cites] Cancer Treat Rep. 1986 Feb;70(2):311-2 [3004729.001]
  • [Cites] Am J Clin Oncol. 1999 Feb;22(1):78-81 [10025387.001]
  • [Cites] Pathol Biol (Paris). 1999 Feb;47(2):216-20 [10192892.001]
  • [Cites] Gynecol Oncol. 1987 Jan;26(1):11-8 [2431962.001]
  • [Cites] Toxicol Appl Pharmacol. 1993 Jul;121(1):160-4 [8337697.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4251-6 [8395979.001]
  • [Cites] Am J Pathol. 1994 Mar;144(3):460-5 [8129031.001]
  • [Cites] Cell. 1995 Jan 27;80(2):285-91 [7834748.001]
  • [Cites] Tohoku J Exp Med. 1995 Sep;177(1):61-71 [8693487.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4743-8 [8840993.001]
  • [Cites] Br J Cancer. 1996 Nov;74(10):1526-33 [8932330.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):29792-8 [8939917.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):1155-60 [9064332.001]
  • [Cites] Blood. 1997 Mar 15;89(6):1845-53 [9058703.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1109-15 [9067280.001]
  • [Cites] Lancet. 1997 Apr 19;349(9059):1137-41 [9113013.001]
  • [Cites] Biosci Rep. 1997 Feb;17(1):67-76 [9171922.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3115-20 [9242435.001]
  • [Cites] J Med Chem. 1997 Aug 1;40(16):2435-9 [9258348.001]
  • [Cites] Hepatology. 1997 Oct;26(4):884-90 [9328309.001]
  • [Cites] J Intern Med Suppl. 1997;740:139-45 [9350196.001]
  • [Cites] Oncogene. 1997 Sep 25;15(13):1573-81 [9380409.001]
  • [Cites] Gastroenterology. 1998 Mar;114(3):536-42 [9496944.001]
  • [Cites] Mol Med. 1998 Jan;4(1):40-5 [9513188.001]
  • [Cites] Cell Biol Toxicol. 1998 Mar;14(2):141-5 [9553725.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2321-5 [9635523.001]
  • [Cites] Biochim Biophys Acta. 1998 Aug 10;1366(1-2):139-49 [9714780.001]
  • [Cites] J Photochem Photobiol B. 1998 Jun 15;44(1):29-38 [9745726.001]
  • [Cites] Chirurg. 1999 Dec;70(12):1397-401 [10637693.001]
  • (PMID = 12235080.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCL2L1 protein, human; 0 / GABA-A Receptor Antagonists; 0 / Isoquinolines; 0 / Mcl1 protein, mouse; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-X Protein; 85340-56-3 / PK 11195
  • [Other-IDs] NLM/ PMC1773378
  •  go-up   go-down


23. Marchini C, Montani M, Konstantinidou G, Orrù R, Mannucci S, Ramadori G, Gabrielli F, Baruzzi A, Berton G, Merigo F, Fin S, Iezzi M, Bisaro B, Sbarbati A, Zerani M, Galiè M, Amici A: Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies. PLoS One; 2010;5(11):e14131
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies.
  • BACKGROUND: Mounting clinical and experimental evidence suggests that the shift of carcinomas towards a mesenchymal phenotype is a common paradigm for both resistance to therapy and tumor recurrence.
  • METHODOLOGY/PRINCIPAL FINDINGS: By integrating in silico and in vitro studies with our epithelial and mesenchymal tumor models, we compare herein crucial molecular pathways of previously described carcinoma-derived mesenchymal tumor cells (A17) with that of both carcinomas and other mesenchymal phenotypes, such as mesenchymal stem cells (MSCs), breast stroma, and various types of sarcomas.
  • By using a recently developed computational approach with publicly available microarray data, we show that these signatures:.
  • 3) are up-regulated after hormonal treatment;.
  • 4) predict resistance to neoadjuvant therapies.
  • CONCLUSIONS/SIGNIFICANCE: Our results demonstrate that mesenchymalization is an intrinsic property of the most aggressive tumors and it relates to therapy resistance as well as bone metastasis.
  • [MeSH-major] Bone Neoplasms / genetics. Breast Neoplasms / genetics. Gene Expression Profiling. Mesoderm / metabolism. Stromal Cells / metabolism
  • [MeSH-minor] Animals. Blotting, Western. Cell Line, Tumor. Cluster Analysis. Cyclooxygenase 2 / genetics. Cyclooxygenase 2 / metabolism. Drug Resistance, Neoplasm / genetics. Epithelial Cells / metabolism. Female. Humans. Mesenchymal Stromal Cells / metabolism. Mice. Neoadjuvant Therapy / methods. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1373-82 [11390357.001]
  • [Cites] Br J Cancer. 2009 May 19;100(10):1575-80 [19384298.001]
  • [Cites] Cancer. 2002 Aug 15;95(4):681-95 [12209710.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1146-51 [14871850.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1655-64 [15084698.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1090-8 [15448693.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6622-8 [15475452.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):761-7 [3160454.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):671-9 [15721472.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3035-9 [15833829.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):197-209 [16169465.001]
  • [Cites] Carcinogenesis. 2005 Nov;26(11):1868-78 [15975963.001]
  • [Cites] Cell. 2005 Dec 16;123(6):1001-11 [16360031.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1037-44 [16505422.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] Histopathology. 2006 Jul;49(1):22-34 [16842243.001]
  • [Cites] J Immunol. 2006 Aug 1;177(3):1526-33 [16849459.001]
  • [Cites] Stem Cells. 2007 Feb;25(2):371-9 [17038675.001]
  • [Cites] Eur J Cancer. 2007 May;43(7):1214-24 [17379505.001]
  • [Cites] Cancer Cell. 2007 May;11(5):421-9 [17482132.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] J Clin Invest. 2007 Nov;117(11):3248-57 [17948129.001]
  • [Cites] Lancet Oncol. 2007 Dec;8(12):1071-8 [18024211.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):989-97 [18281472.001]
  • [Cites] Oncogene. 2008 Apr 17;27(18):2542-51 [17998939.001]
  • [Cites] Nat Med. 2008 May;14(5):518-27 [18438415.001]
  • [Cites] Cell. 2008 May 16;133(4):704-15 [18485877.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6587-97 [18701482.001]
  • [Cites] Nat Med. 2009 Jan;15(1):68-74 [19122658.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1255-8 [19208837.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):2887-95 [19276366.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • (PMID = 21152434.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.14.99.- / Ptgs2 protein, mouse; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ PMC2994727
  •  go-up   go-down


24. Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, Cheng MH, Subramanian A, Mu D, Powers S, Crowley D, Bronson RT, Whittaker CA, Bhutkar A, Lippard SJ, Golub T, Thomale J, Jacks T, Sweet-Cordero EA: Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev; 2010 Apr 15;24(8):837-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer.
  • Chemotherapy resistance is a major obstacle in cancer treatment, yet the mechanisms of response to specific therapies have been largely unexplored in vivo.
  • Employing genetic, genomic, and imaging approaches, we examined the dynamics of response to a mainstay chemotherapeutic, cisplatin, in multiple mouse models of human non-small-cell lung cancer (NSCLC).
  • Prolonged cisplatin treatment promotes the emergence of resistant tumors with enhanced repair capacity that are cross-resistant to platinum analogs, exhibit advanced histopathology, and possess an increased frequency of genomic alterations.
  • We demonstrate a novel role for PIDD as a regulator of chemotherapy response in human lung tumor cells.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1995 Oct 12;377(6549):552-7 [7566157.001]
  • [Cites] Lung Cancer. 2009 Dec;66(3):298-304 [19324449.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):1085-9 [9615770.001]
  • [Cites] Nature. 1999 Jun 24;399(6738):806-9 [10391249.001]
  • [Cites] Mol Cell. 2004 Nov 19;16(4):521-35 [15546613.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):48-55 [15608639.001]
  • [Cites] Nat Rev Drug Discov. 2005 Apr;4(4):307-20 [15789122.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10280-8 [16288016.001]
  • [Cites] Cell. 2005 Dec 16;123(6):1079-92 [16360037.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Apr;45(4):338-48 [16323170.001]
  • [Cites] Nucleic Acids Res. 2006;34(6):e47 [16571898.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11234-9 [16844783.001]
  • [Cites] N Engl J Med. 2006 Sep 7;355(10):983-91 [16957145.001]
  • [Cites] Mol Pharmacol. 2006 Oct;70(4):1390-4 [16847145.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(24):9377-86 [17000754.001]
  • [Cites] EMBO J. 2007 Jan 10;26(1):197-208 [17159900.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1370-80 [17446929.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12117-22 [17626183.001]
  • [Cites] Nat Rev Cancer. 2007 Aug;7(8):573-84 [17625587.001]
  • [Cites] J Neurosci. 2007 Aug 29;27(35):9451-7 [17728458.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16663-8 [17925434.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5240-7 [18024870.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2008;48:495-535 [17937596.001]
  • [Cites] Nat Rev Cancer. 2008 Mar;8(3):193-204 [18256616.001]
  • [Cites] Mol Pharmacol. 2000 Mar;57(3):503-11 [10692490.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1031-7 [10741731.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3155-9 [10866304.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):122-7 [10973264.001]
  • [Cites] Nat Med. 2000 Sep;6(9):1029-35 [10973324.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):418-25 [11694875.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Cell. 2002 May 3;109(3):335-46 [12015983.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4899-902 [12208738.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14298-302 [12370430.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1311-6 [12649192.001]
  • [Cites] Mol Cell. 2003 Apr;11(4):1109-17 [12718895.001]
  • [Cites] Int J Cancer. 2004 Jun 20;110(3):352-61 [15095299.001]
  • [Cites] Science. 2004 May 7;304(5672):843-6 [15073321.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23477-85 [15026414.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4210s-4214s [15217960.001]
  • [Cites] Nature. 1969 Apr 26;222(5191):385-6 [5782119.001]
  • [Cites] Science. 1982 Dec 10;218(4577):1075-82 [6890712.001]
  • [Cites] Carcinogenesis. 1988 Jul;9(7):1283-7 [2898306.001]
  • [Cites] Science. 1990 Mar 23;247(4949 Pt 1):1457-61 [2108497.001]
  • [Cites] J Clin Invest. 1994 Aug;94(2):703-8 [8040325.001]
  • [Cites] Biochemistry. 1995 Jul 4;34(26):8474-80 [7599137.001]
  • [Cites] Nature. 1995 Aug 31;376(6543):785-8 [7651539.001]
  • [Cites] Nature. 2008 Feb 28;451(7182):1116-20 [18264087.001]
  • [Cites] Nature. 2008 Feb 28;451(7182):1111-5 [18264088.001]
  • [Cites] J Biol Chem. 2008 Mar 7;283(10):6572-83 [18162465.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1291-5 [18316546.001]
  • [Cites] Cell. 2009 Feb 6;136(3):508-20 [19203584.001]
  • [Cites] Science. 2009 Jun 12;324(5933):1457-61 [19460966.001]
  • [Cites] Mol Pharmacol. 2009 Jul;76(1):208-14 [19403702.001]
  • [Cites] Cell Cycle. 2009 Oct 15;8(20):3355-64 [19770592.001]
  • [Cites] Cancer Res. 1996 Feb 1;56(3):556-62 [8564971.001]
  • (PMID = 20395368.001).
  • [ISSN] 1549-5477
  • [Journal-full-title] Genes & development
  • [ISO-abbreviation] Genes Dev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R37 CA034992; United States / NCI NIH HHS / CA / P30 CA014051; United States / NCI NIH HHS / CA / 5-UO1-CA84306; United States / NCI NIH HHS / CA / U01 CA084306; United States / NCI NIH HHS / CA / P30-CA14051; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / R01 CA034992; United States / NCI NIH HHS / CA / CA034992; United States / NCI NIH HHS / CA / R01 CA127547
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carrier Proteins; 0 / Death Domain Receptor Signaling Adaptor Proteins; 0 / Lrdd protein, mouse; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2854397
  •  go-up   go-down


25. You S, Zuo L, Li W: Optimizing the time of Doxil injection to increase the drug retention in transplanted murine mammary tumors. Int J Nanomedicine; 2010;5:221-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimizing the time of Doxil injection to increase the drug retention in transplanted murine mammary tumors.
  • It has been proposed that the liposomal formulated doxorubicin (ie, Doxil), given at the menstrual/estrous stage with the predicted highest tumor vascular permeability, allows significantly increased drug retention in the breast tumor.
  • In the current study, syngeneic murine 4T1 mammary tumors were established on the backs of female BALB/c mice and Doxil was administered at particular mouse estrous cycle stages.
  • The results indicated that Doxil administration during certain times in the mouse estrous cycle was crucial for drug retention in 4T1 tumor tissues.
  • Significantly higher drug concentrations were detected in the tumor tissues when Doxil was administered during the diestrus stage, as compared to when the drug injection was given at all other estrous stages.
  • Our study also showed that the tumor-bearing mice exhibited nearly normal rhythmicity of the estrous cycle post drug injection, indicating the feasibility of continual injection of Doxil at the same estrous cycle stage.
  • Some of these factors have been shown to be vascular modulators in diverse tissues.
  • In this report, we demonstrated that the concentration of P4 in the plasma and/or estrous cycle stage of 4T1 tumor-bearing mice can be used to select the best time for administrating the liposomal anticancer drugs.
  • [MeSH-major] Doxorubicin / administration & dosage. Mammary Neoplasms, Experimental / drug therapy. Mammary Neoplasms, Experimental / metabolism
  • [MeSH-minor] Animals. Antibiotics, Antineoplastic / administration & dosage. Dose-Response Relationship, Drug. Female. Injections, Intralesional / methods. Mice. Mice, Inbred BALB C. Treatment Outcome

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drugs. 1997;54 Suppl 4:22-9 [9361958.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Jul;17(1):70-7 [9224211.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2004 Jul-Aug;40(7):187-95 [15161341.001]
  • [Cites] Mol Cancer Ther. 2005 Jul;4(7):1065-75 [16020664.001]
  • [Cites] Int Immunol. 2007 Sep;19(9):1095-102 [17855433.001]
  • [Cites] Int J Exp Pathol. 2007 Oct;88(5):351-60 [17877537.001]
  • [Cites] Cancer Lett. 1997 Oct 28;119(1):79-85 [18372525.001]
  • [Cites] Med Hypotheses. 2008;71(1):141-7 [18299174.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3919-24 [19237581.001]
  • [Cites] Br J Cancer. 1999 Dec;81(8):1311-7 [10604727.001]
  • [Cites] Int J Cancer. 2001 Aug 15;93(4):590-600 [11477565.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Nov;299(2):775-81 [11602694.001]
  • [Cites] Life Sci. 2001 Dec 21;70(5):591-601 [11811903.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):415-22 [12216068.001]
  • [Cites] Life Sci. 2002 Dec 27;72(6):677-87 [12467908.001]
  • [Cites] Biochim Biophys Acta. 2003 Jan 10;1609(1):102-8 [12507764.001]
  • [Cites] Eur J Cancer. 2003 Aug;39(12):1668-75 [12888360.001]
  • [Cites] Oncologist. 2003;8 Suppl 2:3-9 [13679590.001]
  • [Cites] Proc Soc Exp Biol Med. 1976 Nov;153(2):254-7 [1033549.001]
  • [Cites] Biochem Biophys Res Commun. 1986 Apr 29;136(2):521-8 [3010982.001]
  • [Cites] NCI Monogr. 1986;(1):105-9 [3534581.001]
  • [Cites] Cancer Res. 1986 Dec;46(12 Pt 1):6387-92 [2946403.001]
  • [Cites] Biochemistry. 1987 Jun 30;26(13):3776-81 [2820475.001]
  • [Cites] Endocrinology. 1992 Apr;130(4):1923-30 [1547720.001]
  • [Cites] Mol Pharmacol. 1992 Jun;41(6):993-8 [1614415.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):159-65 [9426072.001]
  • (PMID = 20463938.001).
  • [ISSN] 1178-2013
  • [Journal-full-title] International journal of nanomedicine
  • [ISO-abbreviation] Int J Nanomedicine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ PMC2865017
  • [Keywords] NOTNLM ; Doxil / breast cancer therapy / menstrual cycle / mouse mammary tumor / progesterone
  •  go-up   go-down


26. Klinakis A, Szabolcs M, Chen G, Xuan S, Hibshoosh H, Efstratiadis A: Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad Sci U S A; 2009 Feb 17;106(7):2359-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Igf1r as a therapeutic target in a mouse model of basal-like breast cancer.
  • Considering the strong association between dysregulated insulin-like growth factor (IGF) signaling and various human cancers, we have used an expedient combination of genetic analysis and pharmacological treatment to evaluate the potential of the type 1 IGF receptor (Igf1r) for targeted anticancer therapy in a mouse model of mammary tumorigenesis.
  • In this particular strain of genetically modified animals, histopathologically heterogeneous invasive carcinomas exhibiting up-regulation of the Igf1r gene developed extremely rapidly by mammary gland-specific overexpression of constitutively active oncogenic Kras* (mutant Kras(G12D)).
  • Immunophenotyping data and expression profiling analyses showed that, except for a minor luminal component, these mouse tumors resembled basal-like human breast cancers.
  • This is a group of aggressive tumors of poor prognosis for which there is no targeted therapy currently available, and it includes a subtype correlating with KRAS locus amplification.
  • Conditional ablation of Igf1r in the mouse mammary epithelium increased the latency of Kras*-induced tumors very significantly (approximately 11-fold in comparison with the intact model), whereas treatment of tumor-bearing animals by administration of picropodophyllin (PPP), a specific Igf1r inhibitor, resulted in a dramatic decrease in tumor mass of the main forms of basal-like carcinomas.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PODOFILOX .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2001 Jul 5;20(30):3937-48 [11494122.001]
  • [Cites] Genome Biol. 2007;8(5):R76 [17493263.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):236-42 [14729630.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1558-65 [14661057.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):505-18 [15229476.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] J Natl Cancer Inst. 1979 May;62(5):1287-93 [286104.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] J Pharm Sci. 1986 Nov;75(11):1076-80 [3820102.001]
  • [Cites] Nucleic Acids Res. 1987 Aug 11;15(15):5963-71 [3627975.001]
  • [Cites] Adv Anat Pathol. 2007 Sep;14(5):358-73 [17717437.001]
  • [Cites] Eur J Cancer. 2007 Sep;43(13):1895-904 [17624760.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1857-61 [17546599.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1328-32 [17496191.001]
  • [Cites] Histopathology. 2008 Jan;52(1):108-18 [18171422.001]
  • [Cites] Oncologist. 2008 Jan;13(1):16-24 [18245009.001]
  • [Cites] Oncogene. 2008 Mar 6;27(11):1629-38 [17828296.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jan;6(1):101-13 [11467446.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Mamm Genome. 2000 Mar;11(3):196-205 [10723724.001]
  • [Cites] Oncogene. 2000 Jul 6;19(29):3245-55 [10918581.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Int J Cancer. 1991 Apr 1;47(6):833-8 [1672666.001]
  • [Cites] Trends Genet. 1993 Apr;9(4):138-41 [8516849.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11217-21 [8248231.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):3604-12 [8196606.001]
  • [Cites] Development. 1995 Jul;121(7):2079-90 [7635053.001]
  • [Cites] Int J Dev Biol. 1998;42(7):955-76 [9853827.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8804-7 [15604235.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):48-55 [15608639.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4660-71 [15897907.001]
  • [Cites] Expert Opin Ther Targets. 2005 Aug;9(4):753-68 [16083341.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6226-32 [16144925.001]
  • [Cites] Cancer Cell. 2006 Feb;9(2):121-32 [16473279.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1383-91 [16489097.001]
  • [Cites] Nature. 2006 Feb 23;439(7079):993-7 [16395311.001]
  • [Cites] Oncogene. 2006 Apr 6;25(15):2273-84 [16288205.001]
  • [Cites] IDrugs. 2006 Jun;9(6):415-9 [16752311.001]
  • [Cites] BMC Genomics. 2006;7:127 [16729877.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):27-39 [16947084.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 23;354(4):885-91 [17274952.001]
  • [Cites] Mol Cancer Res. 2007 Feb;5(2):195-201 [17314276.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):235-44 [17329194.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Apr 13;355(3):707-14 [17307140.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2329-34 [17438091.001]
  • [Cites] Nat Cell Biol. 2007 May;9(5):493-505 [17450133.001]
  • [Cites] Cell. 2007 Jun 1;129(5):957-68 [17540175.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • (PMID = 19174523.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA097403; United States / NCI NIH HHS / CA / 1 P01 CA97403
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0F35AOI227 / picropodophyllin; EC 2.7.10.1 / Receptor, IGF Type 1; EC 3.6.5.2 / ras Proteins; L36H50F353 / Podophyllotoxin
  • [Other-IDs] NLM/ PMC2650161
  •  go-up   go-down


27. Wicha MS: Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer. Breast Cancer Res; 2009;11(5):108
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent clinical trials demonstrating the efficacy of poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of BRCA1-deficient breast cancer have provided support for the 'synthetic lethal' concept of targeted cancer therapeutics.
  • A new study provides further preclinical validation of this concept by demonstrating that BRCA1-deficient mouse mammary tumor cells are selectively sensitive to an inhibitor of the polycomb gene EZH2.
  • [MeSH-major] BRCA1 Protein / deficiency. Breast Neoplasms / drug therapy. Poly(ADP-ribose) Polymerase Inhibitors
  • [MeSH-minor] Animals. DNA-Binding Proteins / antagonists & inhibitors. Female. Histone-Lysine N-Methyltransferase / antagonists & inhibitors. Humans. Mammary Neoplasms, Experimental / drug therapy. Mammary Neoplasms, Experimental / enzymology. Mammary Neoplasms, Experimental / genetics. Mice. Polycomb Repressive Complex 2. Transcription Factors / antagonists & inhibitors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 [14500907.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):814-9 [15510162.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):913-7 [15829966.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):917-21 [15829967.001]
  • [Cites] J Cell Physiol. 2008 Feb;214(2):295-300 [17786943.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1680-5 [18230721.001]
  • [Cites] Histopathology. 2008 Feb;52(3):370-80 [18269588.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2813-20 [18539959.001]
  • [Cites] Oncogene. 2009 Feb 12;28(6):843-53 [19079346.001]
  • [Cites] Breast Cancer Res. 2008;10(6):R109 [19099573.001]
  • [Cites] Cell. 2009 Mar 20;136(6):1122-35 [19303854.001]
  • [Cites] N Engl J Med. 2009 Jul 9;361(2):123-34 [19553641.001]
  • [Cites] Nat Med. 2009 Aug;15(8):907-13 [19648928.001]
  • [Cites] Breast Cancer Res. 2009;11(4):R63 [19709408.001]
  • [CommentOn] Breast Cancer Res. 2009;11(4):R63 [19709408.001]
  • (PMID = 19804613.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / DNA-Binding Proteins; 0 / Poly(ADP-ribose) Polymerase Inhibitors; 0 / Transcription Factors; EC 2.1.1.43 / EZH2 protein, human; EC 2.1.1.43 / Ezh2 protein, mouse; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.1.1.43 / Polycomb Repressive Complex 2
  • [Other-IDs] NLM/ PMC2790845
  •  go-up   go-down


28. Zhang M, Yao Z, Zhang Z, Garmestani K, Goldman CK, Ravetch JV, Janik J, Brechbiel MW, Waldmann TA: Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. Blood; 2006 Jul 15;108(2):705-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors.
  • Overexpression of CD30 on some neoplasms versus its limited expression on normal tissues makes this receptor a promising target for antibody-based therapy.
  • We investigated the therapeutic efficacy of HeFi-1, a mouse IgG1 monoclonal antibody, which recognizes the ligand-binding site on CD30, and humanized anti-Tac antibody (daclizumab), which recognizes CD25, in a murine model of human ALCL.
  • The ALCL model was established by intravenous injection of karpas299 cells into nonobese diabetic/severe combined immuno-deficient (SCID/NOD) wild-type or SCID/NOD Fc receptor common gamma chain-deficient (FcRgamma(-/-)) mice.
  • HeFi-1, given at a dose of 100 microg weekly for 4 weeks, significantly prolonged survival of the ALCL-bearing SCID/NOD wild-type and SCID/NOD FcRgamma(-/-) mice (P < .01) as compared with the control groups.

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6453-7 [14559836.001]
  • [Cites] Immunity. 2005 Jul;23(1):41-51 [16039578.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5825-9 [15313926.001]
  • [Cites] J Pathol. 2000 Apr;190(5):613-8 [10727988.001]
  • [Cites] Nat Med. 2000 Apr;6(4):443-6 [10742152.001]
  • [Cites] Curr Opin Oncol. 2000 Nov;12(6):588-93 [11085459.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4307-12 [11110706.001]
  • [Cites] Oncogene. 2001 Feb 1;20(5):590-8 [11313991.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):118-29 [11905803.001]
  • [Cites] Nature. 2002 Jun 6;417(6889):584-6 [12050630.001]
  • [Cites] Leuk Lymphoma. 2002 Jul;43(7):1355-66 [12389614.001]
  • [Cites] Nat Med. 2003 Mar;9(3):269-77 [12612576.001]
  • [Cites] Blood. 2003 Jul 1;102(1):284-8 [12649132.001]
  • [Cites] J Immunol. 1981 Apr;126(4):1393-7 [6970774.001]
  • [Cites] J Immunol. 1981 Apr;126(4):1398-403 [6451645.001]
  • [Cites] Bioconjug Chem. 1990 Jan-Feb;1(1):59-65 [2095205.001]
  • [Cites] Cancer Res. 1991 Jul 15;51(14):3781-7 [1648444.001]
  • [Cites] Semin Dermatol. 1991 Sep;10(3):164-71 [1657104.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2834-9 [8504427.001]
  • [Cites] Histopathology. 1993 Aug;23(2):173-8 [8406390.001]
  • [Cites] Am J Pathol. 1995 Feb;146(2):463-71 [7856755.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2139-46 [7718885.001]
  • [Cites] Lancet. 1995 Aug 5;346(8971):336-40 [7623531.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1620-7 [7564499.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5335-41 [7585597.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4063-75 [7492762.001]
  • [Cites] Br J Haematol. 1996 Mar;92(4):872-9 [8616080.001]
  • [Cites] Genes Dev. 1997 Nov 1;11(21):2810-21 [9353251.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):652-6 [9435247.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Br J Cancer. 1999 Jun;80(8):1214-22 [10376974.001]
  • [Cites] Am J Clin Pathol. 1999 Aug;112(2):241-7 [10439805.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1353-9 [10514417.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3355-7 [15205267.001]
  • [Cites] Leuk Lymphoma. 2004 May;45(5):1009-15 [15291361.001]
  • (PMID = 16551968.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD30; 0 / Antigens, Neoplasm; 0 / Immunoglobulin G; 0 / Receptors, Fc; CUJ2MVI71Y / daclizumab
  • [Other-IDs] NLM/ PMC1895489
  •  go-up   go-down






Advertisement